First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer
Authors:
- Torsten KuwertTKTorsten Kuwert
- Michael BeckMBMichael Beck
- James C. SandersJSJames C. Sanders
- Philipp RittPRPhilipp Ritt
- Christian SchmidkonzCSChristian Schmidkonz
- Peter HennigPHPeter Hennig
- Olaf PranteOPOlaf Prante
- Michael UderMUMichael Uder
- Bernd WullichBWBernd Wullich
- Peter GoebellPGPeter Goebell
- 1 January 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (1) , 26-33
Abstract
Aim: Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancers (PCs). Here, we report our first experience using the Tc-99m-labeled PSMA inhibitor MIP-1404 (Progenics Pharmaceuticals, Inc, Tarrytown, NY) in 60 patients with biochemically recurrent PC. Methods: Whole-body planar scintigraphy and SPECT/CT of the lower abdominal pelvic region of 60 patients with biochemical relapse of PC were analyzed retrospectively. In these subjects, an average dose of 733.1 +/- 49.5 MBq (19.8 +/- 1.3 mCi) Tc-99m-labeled MIP-1404 was injected 4 to 5 hours prior to imaging. In addition to visual evaluation, SUVmax were determined in the tumor lesions using a previously developed protocol for quantitative SPECT/CT. Results: In 42 of 60 patients, Tc-99m-MIP-1404-positive lesions could be detected (70%; 95% confidence interval [CI], 0.58-0.82). Twenty patients had Tc-99m-MIP-1404-positive lymph nodes suggestive of metastasis, 14 patients had pathological uptake in the prostate region indicative of local recurrence, and for another 19 patients, there was tracer accumulation in the skeleton (n = 18) or lungs (n = 1). Detection rate was 91.4% (95% CI, 0.82-1) at prostate-specific antigen levels greater than 2 ng/mL and 40.0% (95% CI, 0.21-0.59) at lower prostate-specific antigen values (P < 0.01). Of the 60 patients, in total, 82 positive lesions were analyzed quantitatively. Average SUVmax of the lesions was 16.3 +/- 21.6 with a range of 1.7 to 142.9. Conclusion: Tc-99m-labeled PSMA inhibitor MIP-1404 is a promising SPECT tracer for detection of locally recurrent or metastatic prostate cancer.Keywords
This publication has 40 references indexed in Scilit:
- Imaging in Prostate CarcinomaHematology/Oncology Clinics of North America, 2013
- Imaging of Prostate CarcinomaCancer Control, 2013
- Choline PET or PET/CT and Biochemical Relapse of Prostate CancerClinical Nuclear Medicine, 2013
- Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen RadioimmunotherapyAdvances in Urology, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- ORIGINAL ARTICLE: Pilot comparison of 18F‐fluorocholine and 18F‐fluorodeoxyglucose PET/CT with conventional imaging in prostate cancerJournal of Medical Imaging and Radiation Oncology, 2010
- Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancerLa radiologia medica, 2008
- The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Fluorocholine PET/CT in Patients with Prostate Cancer: Initial ExperienceRadiology, 2005